"Among adults with mild-to-moderate Covid-19 who were at risk for progression, VV116 was noninferior to nirmatrelvir–ritonavir with respect to the time to sustained clinical recovery, with fewer safety concerns."

#COVID #COVID19 #SarsCov2 #Antiviral #nejm

https://www.nejm.org/doi/full/10.1056/NEJMoa2208822?query=featured_home